Plant Name: Geranium carolinianum
Taxonomic Information:
Plant ID: NPO16698
Plant Latin Name: Geranium carolinianum
Taxonomy Genus: Geranium
Taxonomy Family: Geraniaceae
Plant External Links:
NCBI TaxonomyDB:
554690
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| RECQL; TDP1; HPGD; ALOX12; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| FLT3; TEK; MET; INSR; AXL; NUAK1; CDK1; EGFR; PIM1; SRC; KDR; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA14; CA7; CA4; | |
| TYR; | |
| KDM4E; | |
| AHR; | |
| FUT7; | |
| SLC22A6; | |
| LMNA; SMAD3; HSPA1A; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.610E-10 | 2.062E-07 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.461E-10 | 4.223E-07 | AKR1B1, ALOX12, AURKB, AXL, CDK1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, LMNA, PIM1, SMAD3, SRC, TEK |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.538E-08 | 2.366E-05 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 5.745E-08 | 2.406E-05 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.782E-08 | 2.896E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 9.676E-08 | 3.398E-05 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.401E-07 | 6.377E-05 | AKR1B1, APEX1, CA2, CSNK2A1, CYP1A2, EGFR, FLT3, HPGD, INSR, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.946E-07 | 7.308E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.583E-07 | 1.448E-04 | AKR1B1, ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 8.915E-07 | 1.922E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 9.828E-07 | 2.098E-04 | EGFR, INSR, KDR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.402E-06 | 2.880E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.433E-06 | 2.917E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.571E-06 | 6.480E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.384E-06 | 7.761E-04 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.307E-06 | 9.172E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 8.036E-06 | 1.306E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.065E-05 | 1.681E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.167E-05 | 1.828E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.234E-05 | 1.919E-03 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, PIM1, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.258E-05 | 1.930E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.512E-05 | 2.286E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.511E-05 | 2.286E-03 | ACHE, AKR1B1, APEX1, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.526E-05 | 2.292E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.590E-05 | 2.308E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.025E-05 | 2.809E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.025E-05 | 2.809E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 2.108E-05 | 2.887E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 2.641E-05 | 3.412E-03 | ALOX12, CDK1, CSNK2A1, EGFR, INSR, PIM1 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.882E-05 | 3.661E-03 | CYP1A1, LMNA, NOX4, SMAD3, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.175E-05 | 3.859E-03 | CYP1A1, CYP1A2 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 3.208E-05 | 3.859E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 4.138E-05 | 4.768E-03 | AXL, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 4.534E-05 | 5.089E-03 | ACHE, EGFR, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 4.590E-05 | 5.100E-03 | FLT3, SRC, TEK |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.590E-05 | 5.967E-03 | AHR, CSNK2A1, KDR |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 5.733E-05 | 6.060E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 5.847E-05 | 6.110E-03 | ACHE, CDK1, CYP1A1, EGFR, SMAD3 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.865E-05 | 6.110E-03 | ACHE, CSNK2A1, EGFR, FLT3, HPGD, IGF1R, KDR, MET, SLC22A6, SMAD3, SMN1, SMN2, TYR |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 7.302E-05 | 7.260E-03 | APEX1, NOX4, TEK, TYR |
| MF | Unclassified; | GO:0032403; protein complex binding | 7.565E-05 | 7.488E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 7.913E-05 | 7.762E-03 | ALOX12, HPGD |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 8.768E-05 | 8.448E-03 | HSPA1A, MET, NOX4, SMAD3, TEK |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 9.200E-05 | 8.825E-03 | EGFR, KDR, NOX4, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 1.018E-04 | 9.516E-03 | CYP1A1, CYP1A2, KDM4E |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.106E-04 | 9.872E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.106E-04 | 9.872E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.879E-10 | 1.843E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.780E-10 | 1.843E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.010E-08 | 3.844E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.253E-07 | 1.361E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.679E-06 | 4.299E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.126E-05 | 2.059E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.681E-06 | 1.852E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.007E-05 | 1.153E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.093E-04 | 1.166E-03 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 8.800E-05 | 1.153E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 8.403E-05 | 1.153E-03 | INSR, TEK, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.921E-05 | 1.154E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.254E-04 | 2.220E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 4.029E-04 | 3.684E-03 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.611E-04 | 3.853E-03 | FLT3, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.816E-04 | 3.853E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.467E-04 | 4.116E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.088E-04 | 4.775E-03 | HPGD, FLT3, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.930E-04 | 4.217E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.436E-03 | 7.990E-03 | SRC, EGFR, HSPA1A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.022E-03 | 6.229E-03 | SRC, CDK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.325E-04 | 5.328E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.215E-03 | 7.071E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; EGFR; SRC; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
